CRIS Current Research Information System

MARCONI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.747
NA - Nord America 6.163
EU - Europa 4.086
SA - Sud America 418
AF - Africa 412
Continente sconosciuto - Info sul continente non disponibili 398
OC - Oceania 15
Totale 19.239
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.952
VN - Vietnam 2.308
CN - Cina 1.864
SG - Singapore 1.842
IT - Italia 1.095
GB - Regno Unito 750
HK - Hong Kong 451
DE - Germania 443
SE - Svezia 420
BR - Brasile 294
KR - Corea 291
FR - Francia 273
IN - India 247
NL - Olanda 230
BD - Bangladesh 198
RU - Federazione Russa 161
FI - Finlandia 151
JP - Giappone 141
IE - Irlanda 136
CA - Canada 115
CI - Costa d'Avorio 93
TG - Togo 91
ZA - Sudafrica 88
NG - Nigeria 58
ID - Indonesia 53
SC - Seychelles 52
BG - Bulgaria 51
JO - Giordania 51
EE - Estonia 48
CH - Svizzera 46
AR - Argentina 45
BE - Belgio 44
PH - Filippine 44
TH - Thailandia 42
UA - Ucraina 40
PL - Polonia 38
ES - Italia 34
MX - Messico 34
IQ - Iraq 31
AT - Austria 29
TR - Turchia 28
TW - Taiwan 24
IR - Iran 23
EC - Ecuador 21
CO - Colombia 20
GR - Grecia 19
UZ - Uzbekistan 19
PK - Pakistan 18
JM - Giamaica 14
LT - Lituania 14
HR - Croazia 13
PY - Paraguay 12
AU - Australia 11
SA - Arabia Saudita 10
VE - Venezuela 10
CL - Cile 9
CR - Costa Rica 9
RO - Romania 9
EG - Egitto 8
AE - Emirati Arabi Uniti 7
KZ - Kazakistan 7
MY - Malesia 7
TT - Trinidad e Tobago 7
AL - Albania 6
EU - Europa 6
GT - Guatemala 5
HN - Honduras 5
LB - Libano 5
MA - Marocco 5
MK - Macedonia 5
NP - Nepal 5
PT - Portogallo 5
QA - Qatar 5
RS - Serbia 5
SV - El Salvador 5
DZ - Algeria 4
HU - Ungheria 4
KE - Kenya 4
NZ - Nuova Zelanda 4
PE - Perù 4
CZ - Repubblica Ceca 3
LV - Lettonia 3
NI - Nicaragua 3
OM - Oman 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
AZ - Azerbaigian 2
CY - Cipro 2
DK - Danimarca 2
ET - Etiopia 2
GE - Georgia 2
IL - Israele 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
LC - Santa Lucia 2
PS - Palestinian Territory 2
A2 - ???statistics.table.value.countryCode.A2??? 1
Totale 18.821
Salva come PNG Salva come JPEG
Città #
Singapore 1.342
Ashburn 739
Dong Ket 639
Southend 631
Hefei 529
Chandler 438
Ho Chi Minh City 415
San Jose 404
Hong Kong 400
Hanoi 359
Ann Arbor 292
Fairfield 264
Seoul 259
Beijing 222
Bologna 206
Santa Clara 202
Houston 159
Boardman 155
Council Bluffs 148
Dallas 146
Wilmington 145
New York 143
Los Angeles 142
Seattle 141
Woodbridge 138
Dublin 135
Tokyo 123
Princeton 118
Cambridge 110
Helsinki 99
Lauterbourg 97
Abidjan 93
Lomé 91
Milan 88
São Paulo 69
Haiphong 64
Da Nang 59
Rome 57
Buffalo 55
Munich 53
Nanjing 53
Frankfurt am Main 51
Sofia 51
Westminster 51
Amman 49
Bengaluru 49
Brussels 43
Medford 43
Padova 43
Redondo Beach 43
Abeokuta 41
Shanghai 39
Guangzhou 38
Phoenix 38
Jakarta 36
Turin 34
Berlin 33
Bremen 33
Lappeenranta 32
Johannesburg 31
Toronto 31
Redmond 30
Redwood City 30
Chicago 29
Bern 28
Florence 28
Montreal 28
London 27
Shenyang 27
Hải Dương 26
Nuremberg 26
Jinan 24
Atlanta 23
San Diego 22
Tianjin 22
Zhengzhou 22
Biên Hòa 21
Falkenstein 21
Saint Petersburg 21
Warsaw 21
Amsterdam 20
Hebei 20
Turku 19
Changsha 18
Nanchang 18
Orem 18
Paris 18
San Francisco 18
Vienna 18
Chengdu 17
Manchester 17
Brooklyn 16
Naples 16
Tongling 16
Bangkok 15
Hangzhou 15
Hyderabad 15
Jiaxing 15
Mexico City 15
Ninh Bình 15
Totale 11.646
Salva come PNG Salva come JPEG
Nome #
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 413
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 329
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 323
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 306
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 294
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 281
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 268
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 262
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 259
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 258
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 257
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 251
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 246
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 245
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 243
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 242
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 237
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 236
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 236
Safety Run-In and Part 1 of GIMEMA AML1718: Venetoclax Combined with FLAI as Induction Treatment in Non-Low-Risk AML 228
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 224
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 219
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 218
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 215
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 215
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents 213
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 213
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 213
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 212
ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment 210
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 208
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 207
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol 205
Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations 205
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 205
INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia 204
Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 199
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 197
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 197
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway 195
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 193
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia 190
You have accessEx-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 190
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 189
Enhance the Efficacy of Doxorubicin Destabilizing the G2/M Checkpoint with a CHK1/CHK2 Inhibitor Pre-Treatment on Acute Lymphoblastic Leukemia 188
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 188
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 184
Exploring the role of PARP1 inhibition in enhancing antibody–drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions 183
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3‐mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real‐life setting 182
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 181
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 178
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT) 177
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 177
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 176
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 176
Override the doxorubicin-induced G2/M checkpoint using cell-cycle checkpoint inhibitors on acute lymphoblastic leukemia 174
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 172
SNP array reveals a new deletion of JAK2 in AML patients 172
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 171
A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination 171
Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy 167
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease 166
Description of 18 PNH patients with prevalent GPI‐deficient monocytes. An Italian survey 164
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 162
Genomic wide microarray analysis identifies novel copy number alterations in adult acute myeloid leukemia 162
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 161
Acute Myeloid Leukemia: Updates on Diagnosis, Treatment and Management 160
Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels 160
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 159
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 158
Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia 156
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia 154
Synergism through WEE1 and CHK1 inhibition in acute lymphoblastic leukemia 153
Novel insights and therapeutic approaches in secondary AML 151
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies 149
INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia 147
PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study 145
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (Nature Communications, (2021), 12, 1, (6233), 10.1038/s41467-021-26551-x) 141
Low WT1 Expression Identifies a Subset of Acute Myeloid Leukemia with a Distinct Genotype 139
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment 133
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 133
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 133
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 125
Safety of FLT3 inhibitors in patients with acute myeloid leukemia 123
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax / hypomethylating agents 123
Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement 121
Pharmacological inhibition of wip1 sensitizes acute myeloid leukemia cells to the mdm2 inhibitor nutlin-3a 119
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 110
Biological therapy in elderly patients with acute myeloid leukemia 106
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 105
Hemophagocytic lymphohistiocytosis in gastric cancer: A rare syndrome for the oncologist. Case report and brief review 103
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS 101
Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study 99
Editorial: Precision medicine for acute myeloid leukemia 98
Personalizing precision medicine: Patients with AML perceptions about treatment decisions 96
Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia 95
Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia 89
Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial 87
Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm 78
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia 77
Totale 18.408
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.015
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.015
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.307 0 0 70 145 129 72 46 120 76 105 305 239
2022/20231.834 206 261 96 222 164 134 60 96 310 49 139 97
2023/2024669 22 66 48 71 31 139 61 65 42 46 49 29
2024/20252.836 88 369 207 187 220 103 378 127 34 278 244 601
2025/20268.393 817 877 624 725 709 335 847 217 1.752 680 392 418
2026/2027750 267 270 213 0 0 0 0 0 0 0 0 0
Totale 19.239